Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
302
-
Total 13F shares, excl. options
-
86M
-
Shares change
-
-2.48M
-
Total reported value, excl. options
-
$4.77B
-
Value change
-
-$111M
-
Put/Call ratio
-
0.82
-
Number of buys
-
163
-
Number of sells
-
-122
-
Price
-
$55.55
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q3 2024
349 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q3 2024.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 302 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 86M shares
of 96M outstanding shares and own 89.57% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (9.95M shares), BlackRock, Inc. (5.83M shares), SANDS CAPITAL MANAGEMENT, LLC (5.12M shares), WELLINGTON MANAGEMENT GROUP LLP (4.17M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.07M shares), ALKEON CAPITAL MANAGEMENT LLC (3.01M shares), STATE STREET CORP (2.66M shares), Clearbridge Investments, LLC (2.43M shares), FEDERATED HERMES, INC. (2.11M shares), and Rock Springs Capital Management LP (1.98M shares).
This table shows the top 302 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.